Answers are grounded in this paper and cite their sources.
To explore the clinical applicability of the Goldie and Coldman hypothesis, we treated 28 patients with metastatic breast cancer with alternating non-cross-resistant chemotherapy. The patients received cyclophosphamide, 600 mg/m 2 , 5-fluorouracil, 600 mg/m 2 , methotrexate, 40 mg/m 3 , alternated every three weeks with adriamycin, 60 mg/m 2 , and mitomycin C, 10 mg/m 2 . Only one patient had previously received palliative chemotherapy. Six patients had received adjuvant CMF, and 17 patients had been pretreated with endocrine therapy (13 for advanced disease, 4 as adjuvant). Fourteen patients had bone involvement, and 10 had visceral metastases. A mean of 12 cycles was given to 24 evaluable patients. The objective response rate was 67%: 11 patients (46%) achieved complete and 5 (21%) partial remission. Response rate in soft tissues was 83.3%, in bone 50%, in liver 100%, and in lung 80%. The median duration of response was 14 months, with 7 patients still in remission. No life-threatening toxicity was observed. Our preliminary results support the validity of this approach and the efficacy of this combination chemotherapy. A large-scale randomized study is warranted.
No takes yet. Share an insight, caveat, or question.
Cruciani et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: